Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 19.92% is 157% above its 5-year average of -34.79%, near the high end of its 5-year range (-54.79%–19.92%).
139.25% above its 12-month average of -50.75%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 40.54%.
RETURN ON ASSETS (ROA)
19.92%
RETURN ON ASSETS (ROA) AVG TTM
-50.75%
RETURN ON ASSETS (ROA) AVG 3Y
-41.99%
RETURN ON ASSETS (ROA) AVG 5Y
-34.79%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+139.25%
CURRENT VS 3Y AVG
+147.44%
CURRENT VS 5Y AVG
+157.25%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+161.79%
vs the sector median at left
MeiraGTx Holdings plc
Market Cap
$978.27M
Return on Assets (ROA)
19.92%
TTM Avg
-50.75%
3Y Avg
-41.99%
5Y Avg
-34.79%
Market Cap
$981.32M
Return on Assets (ROA)
-23.69%
TTM Avg
-98.11%
3Y Avg
-69.18%
5Y Avg
-69.18%
Market Cap
$970.39M
Return on Assets (ROA)
1.18%
TTM Avg
-2.92%
3Y Avg
-0.56%
5Y Avg
1.87%
Market Cap
$986.21M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$988.10M
Return on Assets (ROA)
-22.90%
TTM Avg
-17.96%
3Y Avg
-22.57%
5Y Avg
-25.02%
Market Cap
$994.74M
Return on Assets (ROA)
130.50%
TTM Avg
-115.89%
3Y Avg
-79.68%
5Y Avg
-67.37%
Market Cap
$957.40M
Return on Assets (ROA)
-72.50%
TTM Avg
-45.97%
3Y Avg
-37.50%
5Y Avg
-37.52%
Market Cap
$1.00B
Return on Assets (ROA)
-56.27%
TTM Avg
-37.98%
3Y Avg
-21.94%
5Y Avg
-21.15%
Market Cap
$952.79M
Return on Assets (ROA)
-13.12%
TTM Avg
-18.77%
3Y Avg
-18.48%
5Y Avg
-18.48%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | $978.27M | 19.92% | -50.75% | -41.99% | -34.79% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $981.32M | -23.69% | -98.11% | -69.18% | -69.18% |
| Pacira BioSciences, Inc. (PCRX)vs › | $970.39M | 1.18% | -2.92% | -0.56% | 1.87% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $986.21M | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $988.10M | -22.90% | -17.96% | -22.57% | -25.02% |
| Vor Biopharma Inc. (VOR)vs › | $994.74M | 130.50% | -115.89% | -79.68% | -67.37% |
| Savara Inc. (SVRA)vs › | $957.40M | -72.50% | -45.97% | -37.50% | -37.52% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.00B | -56.27% | -37.98% | -21.94% | -21.15% |
| Aktis Oncology, Inc. (AKTS)vs › | $952.79M | -13.12% | -18.77% | -18.48% | -18.48% |
| Immatics N.V. (IMTX)vs › | $1.01B | -43.17% | -16.38% | -11.13% | -30.16% |
ROA
19.9%
ROE
36.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -46.72% |
| 2024-12-31 | -54.79% |
| 2023-12-31 | -25.72% |
| 2022-12-31 | -40.73% |
| 2021-12-31 | -24.85% |
| 2020-12-31 | -15.95% |
| 2019-12-31 | -16.90% |
| 2018-12-31 | -85.52% |
| 2017-12-31 | -120.08% |
| 2016-12-31 | -86.41% |
